MDRNA Gets $1M Milestone as It Ekes Value from Non-RNAi Programs | GenomeWeb

MDRNA announced this week that it has received a $1 million milestone payment from Amylin Pharmaceuticals related to a 2006 deal between the companies to develop a nasal-spray formulation of the diabetes drug exenatide.

According to MDRNA, the payment was made on an accelerated basis after the companies amended their original 2006 agreement. Under the amended arrangement, MDRNA could receive up to $79 million in additional milestones, the company added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

A Karmagenes researcher has lost his position after reportedly admitting to data fabrication, according to Retraction Watch.

Two neuroscientists write in Nature News that solving the "reproducibility crisis" in science may require changing the requirements for publication.